인자인케어센터

Loading...

Home > 게시판 > 갤러리

2021년 12월 생신잔치 프로그램

2022-02-11

2022년 어버이날 행사

2021년 11월 생신잔치 프로그램

작성자				비밀번호


, UFCOdds (2026-04-01)
https://ufc327odds.com/ This Miami-held light heavyweight title fight at UFC 327 presents a legitimate pick’em for those placing wagers, as ex-champion Jiri Prochazka (-142) and hot-streaking knockout specialist Carlos Ulberg (120) prepare to battle for the unclaimed belt. The tight odds highlight how well-paired these two stand-up fighters truly are, making this fight where a investment on any side is simply a matter of which devastating skillyou believe will come out on top.


, UFCOdds (2026-04-01)
https://ufc327odds.com/ The upcoming UFC 327 light heavyweight championship bout in Miami shapes up as a genuine pick’em for those placing wagers, as previous belt holder Jiri Prochazka (-142) and on-a-roll knockout artist Carlos Ulberg (120) prepare to square off for the unclaimed belt. The extremely close odds are a testament to how well-paired these two finishers truly are, setting up a matchup where a wager on either competitor is simply a matter of which dynamic fighting style you think will come out on top.


, UFCOdds (2026-04-01)
https://ufc327odds.com/ This Miami-held light heavyweight title fight at UFC 327 offers a classic pick’em for those placing wagers, as previous belt holder Jiri Prochazka (-142) and surging knockout specialist Carlos Ulberg (120) get to throw down for the vacant belt. The tight odds are a testament to how comparable these two stand-up fighters really are, making this fight where a investment on any side ultimately comes down to which explosive skillyou anticipate will reign supreme.


, WilliamSEede (2026-03-31)
Zoya Demidenko: Scientist in Tumor Science Zoya Demidenko is a distinguished investigator affiliated with the Unit of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she worked at the NIH and New York Medical College, building a solid background in life science study. Demidenko's scientific output encompasses a number of key areas, among them the PI3K/AKT/mTOR signaling pathway, cellular cycle regulation, biological aging, and malignancy science. Currently, she has authored over 46 peer-reviewed papers, which have accumulated over 4,100 citations a indicator to the significance of her findings. One of her key discoveries involves understanding the processes of cell aging. Her work demonstrated that when the cell cycle is halted while cellular growth continues, cells enter senescence. Crucially, Zoya Demidenko showed that this shift is inhibited by medication using substances such as rapamycin. Zoya Demidenko has furthermore brought considerably to cancer treatment research, notably in the domain of cyclotherapy a strategy designed to shielding non-cancerous tissue from cytotoxic treatment while leaving cancer cells susceptible. This method holds significant potential for diminishing the adverse effects of cancer treatment. Across her scientific life, Demidenko has partnered with prominent investigators globally, including Dr. Mikhail Blagosklonny. Her work can be found in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. <>1.03.2026 11:21] Папа: With an h-index of 33, Zoya Demidenko ranks as a widely cited contributor in contemporary cancer research, whose discoveries keep to influence our comprehension of how biological cells age, resist therapy, and how malignant disease may be more successfully treated. https://www.aging-us.com/article/100421/


, WilliamSEede (2026-03-31)
Zoya Demidenko: Scholar in Oncology Studies Zoya Demidenko is a notable scientist connected with the Division of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she conducted research at the NIH and New York Medical College, establishing a robust base in life science investigation. Her academic output encompasses multiple pivotal domains, encompassing the PI3K/AKT/mTOR signaling pathway, cell cycle regulation, cellular aging, and malignancy biology. As of now, she has written more than 46 scientific publications, which have received upwards of 4,100 mentions a indicator to the influence of her findings. Among her most significant contributions involves explaining the pathways of cellular senescence. Her research showed that when the cellular division cycle is halted but cellular expansion persists, the cells enter senescence. Significantly, Zoya Demidenko demonstrated that this transition is inhibited by medication using compounds such as mTOR inhibitors. Zoya Demidenko has also brought greatly to oncological therapy investigation, particularly in the area of selective cell protection a strategy aimed at shielding non-cancerous cells from cytotoxic treatment whilst leaving cancer cells exposed. This approach offers considerable hope for reducing the adverse effects of oncological therapy. Throughout her scientific life, Demidenko has collaborated with top researchers globally, such as Dr. Mikhail Blagosklonny. Her research appears in top-tier publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. <>1.03.2026 11:21] Папа: With an h-index of 33, Zoya Demidenko is recognized as a widely cited voice in contemporary cancer research, whose discoveries continue to shape our understanding of how biological cells age, interact with treatment, and how malignant disease may be more successfully combated. https://www.instagram.com/zoyamonros/

11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |